Concepedia

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

François Venter, Simiso Sokhela, Bryony Simmons, Michelle Moorhouse, Lee Fairlie, Nkuli Mashabane, Celicia Serenata, Godspower Akpomiemie, Masebole Masenya, Ambar Qavi,

The Lancet HIV · 2020 · 260 citations · 17 references

Open access

References

17

Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories

Kyle J Foreman, Neal Marquez, Andrew J. Dolgert et al. · The Lancet · 2018 · 3K citations · Full text

Public Health, Health Policy, Health Sciences +16

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

François Venter, Michelle Moorhouse, Simiso Sokhela et al. · New England Journal of Medicine · 2019 · 717 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana

Rebecca Zash, Lewis B. Holmes, Modiegi Diseko et al. · New England Journal of Medicine · 2019 · 394 citations · Full text

Medicine, Infectious Diseases, Obstetrics +17

Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy

Kassem Bourgi, Peter F. Rebeiro, Megan Turner et al. · Clinical Infectious Diseases · 2019 · 327 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +15

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

Richard Haubrich, Sharon A. Riddler, A. Gregory DiRienzo et al. · AIDS · 2009 · 256 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17